Shiela Haffar, MD
Medical Oncology · Mesquite, TXNPI 1720010507
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Bristol Myers Squibb at 53.0% of the total. Reporting peaked in 2019 at $2,604 and has fallen 88.0% since, to $313 in 2025. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 95 payments — averaging $48.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$2K
- Novartis$456
- Athenex Pharmaceutical Division, LLC$350
- Novocure GmbH$250
- Gilead$208
- GSK$105
- plus $796 from 25 others
Across 423 payments — averaging $1139.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$201K
- Amgen$122K
- Pfizer$45K
- Eli Lilly$38K
- E.r. Squibb & Sons, L.L.C.$33K
- Pharmacyclics LLC, An Abbvie Company$27K
- plus $17K from 3 others
What the payments were for
- Consulting fees$2,31050%
- Speaking & faculty fees$60013%
- Food & beverage$1,64236%
- Education$521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $2,440 |
| Novartis | 26 | $456 |
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| Novocure GmbH | 1 | $250 |
| Gilead(2 entities) | 11 | $208 |
| GSK | 5 | $105 |
| E.r. Squibb & Sons, L.L.C. | 7 | $100 |
| AbbVie | 4 | $75 |
| Pfizer | 4 | $60 |
| Astellas Pharma US Inc | 4 | $55 |
| Array Biopharma Inc | 3 | $49 |
| Stemline Therapeutics Inc. | 2 | $39 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Johnson & Johnson | 2 | $35 |
| Genentech USA, Inc. | 2 | $33 |
| Puma Biotechnology, Inc. | 1 | $30 |
| Merck | 2 | $29 |
| Bayer | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Tempus AI, Inc | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| Morphosys, US Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| GE HealthCare | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Beigene USA, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Sirtex Medical Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Revlimid$2,424
How this compares
$4,605 in reported general payments places this provider in the 50th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 59 | $689,353 |
| IbrancePalbociclib | 39 | $612,829 |
| RevlimidLenalidomide | 31 | $585,509 |
| InlytaAxitinib | 11 | $223,369 |
| Lenalidomide | 14 | $203,148 |
| JakafiRuxolitinib Phosphate | 12 | $116,931 |
| XareltoRivaroxaban | 70 | $70,684 |
| Letrozole | 248 | $6,649 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $2,030 |
| Morphine Sulfate ErMorphine Sulfate | 18 | $1,504 |
| Tamoxifen Citrate | 55 | $1,363 |
| Hydroxyurea | 57 | $1,356 |
| Dexamethasone | 39 | $730 |
| Anastrozole | 34 | $656 |
| Gabapentin | 33 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta | $60 | $836,19850 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $38 | $689,35359 claims |
| Bristol Myers SquibbRevlimid | $2,440 | $585,50931 claims |
| Johnson & JohnsonXarelto | $35 | $70,68470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Mesquite
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.